Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs

See what CB Insights has to offer

Founded Year

1998

Stage

Unattributed | Alive

Total Raised

$47.55M

Last Raised

$1M | 10 yrs ago

About Koronis Pharmaceuticals

Koronis Pharma develops antiviral therapeutics based on Viral Decay Acceleration, which exploits the strength of a virus to target its collapse.

Koronis Pharmaceuticals Headquarter Location

800 Fifth Avenue Suite 4120

Seattle, Washington, 98104,

United States

206-682-1181

Latest Koronis Pharmaceuticals News

Venture-backed Koronis Plans I.P.O.

Mar 14, 2011

March 14, 2011 Koronis Pharmaceuticals, a venture-backed developer of drugs for HIV, is planning an initial public offering in London for later this year, or early 2012, Reuters reported. Seattle-based Koronis has raised $43 million to date from investors. It is majority-owned by Pacific Horizon Ventures, a Seattle-based venture capital firm, Reuters said. The company’s drugs are designed to accelerate mutation of the virus that causes AIDS to the point where it collapses, Reuters wrote. (Reuters) – Koronis Pharmaceuticals, a privately held U.S. biotech firm working on a new kind of HIV drug, is looking to list in London later this year or early in 2012, its chief executive said. Seattle-based Koronis — pioneering a new HIV drug designed to accelerate mutation of the virus that causes AIDS to the point where it collapses — needs around $15 million to take its experimental product to the next stage of clinical tests. CEO Donald Elmer said he had been in talks with banks in London because raising small sums of that size was no longer feasible on the Nasdaq market in the United States, given the heavy costs of maintaining a listing there. He aims to raise the cash needed to take Koronis’s “viral decay acceleration” drug KP-1461 into further mid-stage Phase II studies via either an initial public offering (IPO) on London’s Alternative Investment Market (AIM) or by reversing into a listed entity with a cash balance. “The practical problem today is that Nasdaq is out of reach for many companies that are at the size of Koronis and the AIM market is an ideal intermediate rung for company looking to raise 10-15 million pounds,” he said in a telephone interview. So far, KP-1461 has been tested in short clinical trials on around 80 patients with no ill-effect. Now Koronis needs to conduct longer-term tests to see if it really can reduce the amount of virus circulating in patients’ blood. If it works, the new drug could mark a major change in HIV/AIDS treatment. Existing drugs all work by suppressing virus function and must be taken in life-long cocktail combinations. KP-1461 would be the first non-suppressive therapy. Katherine Xu, an analyst at Wedbush Securities, said in a research note in January that the approach was potentially “game changing” for the $12 billion-a-year HIV market, although it was still at a very early stage and therefore highly uncertain. Leading players in HIV treatment at present include Gilead (GILD.O) and ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK.L) and Pfizer (PFE.N). Koronis has to date raised $43 million in a series of private fund-raisings. It is majority-owned by Pacific Horizon Ventures, a Seattle-based venture capital firm. (Editing by Louise Heavens) © 2015 Buyouts Insider / Argosy Group LLC

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Koronis Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Koronis Pharmaceuticals is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

I

Infectious Disease

2,330 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

B

Biopharmaceuticals

5,726 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Koronis Pharmaceuticals Patents

Koronis Pharmaceuticals has filed 5 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/16/2011

12/4/2012

Prodrugs, Vaccines, Animal viral diseases, Animal virology, Virology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/16/2011

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

12/4/2012

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Prodrugs, Vaccines, Animal viral diseases, Animal virology, Virology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.